Search results for "Lymphoblast"

showing 10 items of 107 documents

Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia

2002

Background Antimetabolite-based continuation therapy is commonly used for childhood acute lymphoblastic leukemia (ALL) and hypoglycemia after prolonged fasting has been recently reported. We have found that spontaneous, symptomatic hypoglycemia (SH) may also occur in such patients. Procedure Between 1995 and 1999, patients treated according to the AIEOP-ALL-95 study received BFM-type intensive chemotherapy; mercaptopurine (6-MP) was given (60 mg/m2/days, orally for 14 days) during the second part of induction and during consolidation therapy (25 mg/m2/day, orally for 8 weeks); thioguanine (6-TG) was given during reinduction therapy with protocol II (60 mg/m2/day, orally for 14 days); contin…

Cancer ResearchChemotherapyVincristinemedicine.medical_specialtymedicine.drug_classbusiness.industrymedicine.medical_treatmentHypoglycemiamedicine.diseaseGastroenterologyMercaptopurineAntimetaboliteSurgeryTioguanineOncologyAcute lymphocytic leukemiaInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessChildhood Acute Lymphoblastic Leukemiamedicine.drugMedical and Pediatric Oncology
researchProduct

Cancer stem cell definitions and terminology:the devil is in the details

2012

The cancer stem cell (CSC) concept has important therapeutic implications, but its investigation has been hampered both by a lack of consistency in the terms used for these cells and by how they are defined. Evidence of their heterogeneous origins, frequencies and their genomic, as well as their phenotypic and functional, properties has added to the confusion and has fuelled new ideas and controversies. Participants in The Year 2011 Working Conference on CSCs met to review these issues and to propose a conceptual and practical framework for CSC terminology. More precise reporting of the parameters that are used to identify CSCs and to attribute responses to them is also recommended as key t…

Cancer ResearchGeneral MathematicsACUTE MYELOID-LEUKEMIAPERIPHERAL-BLOODBiologyAnimals; Cell Differentiation; Cell Transformation Neoplastic; Clonal Evolution; Humans; Neoplastic Stem Cells; Terminology as Topic; Oncology; Cancer ResearchBioinformaticsCell TransformationSomatic evolution in cancerTumor Initiating CellsTerminologyClonal EvolutionIN-VITRO PROPAGATIONPHENOTYPIC HETEROGENEITYREPOPULATING CELLSConsistency (negotiation)Cancer stem cellCancer stem cells (CSC)Settore MED/04 - PATOLOGIA GENERALETerminology as TopicmedicineAnimalsHumansIn patientACUTE LYMPHOBLASTIC-LEUKEMIAGENE-EXPRESSIONConfusionSettore MED/04 - Patologia GeneraleMELANOMA-CELLSCognitive scienceNeoplasticAnimalApplied MathematicsSTEM/PROGENITOR CELLSCell DifferentiationTUMOR-INITIATING CELLSPeripheral bloodCell Transformation Neoplasticcancer stem cells differentiation tumor definitionsOncologyNeoplastic Stem CellsNeoplastic Stem Cellmedicine.symptomHuman
researchProduct

Immune Therapy of Lympho-Hemopoietic Malignancies.

2017

Cancer ResearchImmunoconjugatesbusiness.industryAntibodies MonoclonalHematologyPrecursor Cell Lymphoblastic Leukemia-LymphomaImmune therapy03 medical and health sciencesHaematopoiesis0302 clinical medicineTreatment OutcomeOncologyLeukemia Myeloid030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyAcute DiseaseMedicineHumans030212 general & internal medicineImmunotherapybusinessOncology research and treatment
researchProduct

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic proge…

2001

Stromal cell-derived factor-1alpha (SDF-1alpha) is a potent chemoattractant for hematopoietic progenitor cells (HPC), suggesting that it could play an important role during their migration within or to the bone marrow (BM). The integrin VLA-4 mediates HPC adhesion to BM stroma by interacting with CS-1/fibronectin and VCAM-1. It is required during hematopoiesis and homing of HPC to the BM. As HPC migration in response to SDF-1alpha might require dynamic regulation of integrin function, we investigated if SDF-1alpha could modulate VLA-4 function on BM CD34(hi) cells.CD34(hi) BM cells and hematopoietic cell lines were tested for the effect of SDF-1alpha on VLA-4-dependent adhesion to CS-1/fibr…

Cancer ResearchIntegrinsReceptors CXCR4Stromal cellIntegrinCD34Receptors Lymphocyte HomingVascular Cell Adhesion Molecule-1Bone Marrow CellsIntegrin alpha4beta1Hematopoietic Cell Growth FactorsCell LineColony-Forming Units Assaychemistry.chemical_compoundMiceLeukemia Megakaryoblastic AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGeneticsCell AdhesionTumor Cells CulturedAnimalsHumansVCAM-1Cell adhesionMolecular BiologybiologyChemotaxisVLA-4Antibodies MonoclonalCell BiologyHematologyHematopoietic Stem CellsChemokine CXCL12Peptide FragmentsRecombinant ProteinsCell biologyFibronectinsFibronectinchemistryLiverbiology.proteinStromal CellsChemokines CXCHoming (hematopoietic)Signal TransductionExperimental hematology
researchProduct

Early deaths in acute lymphoblastic leukemia (ALL): results of the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP).

1984

In this retrospective multicentric study, we report on early deaths (ie, those that occurred during the first month of treatment) in a total of 943 newly diagnosed ALL pediatric patients registered from 1976 to 1981 at 21 centers of the AIL-AIEOP. Objectives of this study were as follows: (1) to verify the incidence and the cause of early death in a wide population of children with ALL and (2) to elucidate factors associated with early death and therefore to identify “high-risk” groups of patients. Out of the 943 ALL patients, 39 (4.1%) early deaths were registered. Main causes were infection, 20 patients (51.3%); hemorrhage, 11 patients (28.3%); uric acid nephropathy, 2 patients (5.1%); ca…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentHeart DiseasesLymphoblastic LeukemiaPopulationEarly deathHemorrhageInfectionsMediastinal NeoplasmsNephropathyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationChildRetrospective Studieseducation.field_of_studyAcute leukemiabusiness.industryIncidence (epidemiology)Age FactorsMediastinumInfantmedicine.diseasePrognosisLeukemia Lymphoidmedicine.anatomical_structureOncologyChild PreschoolPediatrics Perinatology and Child HealthSyndrome of inappropriate antidiuretic hormone secretionKidney DiseasesbusinessMedical and pediatric oncology
researchProduct

Atopic disease and childhood acute lymphoblastic leukemia

2003

Our objective was to test the hypothesis that the risk of childhood leukemia is associated with allergies or a family history of allergy. We used a German population-based case-control study with self-reported information on allergies of the children and their first-degree relatives. Our study included a total of 1,130 cases of acute lymphoblastic leukemia (ALL), 164 cases of acute myeloid leukemia (AML) and 2,957 controls. A major finding of our study is that hay fever, neurodermatitis and contact eczema are underrepresented within the group of children with ALL, with respective odds ratios (OR) of 0.45 (95% confidence interval [CI] 0.31-0.66) for hay fever, of 0.49 (CI 0.34-0.71) for neur…

Cancer ResearchPediatricsmedicine.medical_specialtyAllergyChildhood leukemiabusiness.industrymedicine.diseaseAtopyOncologyAcute lymphocytic leukemiamedicineHay feverRisk factorNeurodermatitisbusinessChildhood Acute Lymphoblastic LeukemiaInternational Journal of Cancer
researchProduct

Fetal growth and childhood acute lymphoblastic leukemia: Findings from the childhood leukemia international consortium

2013

Positive associations have been reported between measures of accelerated fetal growth and risk of childhood acute lymphoblastic leukemia (ALL). We investigated this association by pooling individual-level data from 12 case-control studies participating in the Childhood Leukemia International Consortium. Two measures of fetal growth – weight-for-gestational-age and proportion of optimal birth weight (POBW) – were analysed. Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression, and combined in fixed effects meta-analyses. Pooled analyses of all data were also undertaken using multivariable logistic regression. Subgroup analy…

Cancer ResearchPediatricsmedicine.medical_specialtyChildhood leukemiabusiness.industryBirth weightCase-control studyGestational ageOdds ratiomedicine.diseaseLogistic regressionConfidence intervalOncologyInternal medicinemedicinebusinessChildhood Acute Lymphoblastic LeukemiaInternational Journal of Cancer
researchProduct

Molecular cytogenetics of childhood hematological malignancies

1998

Cytogenetic and molecular analyses are essential for the classification of childhood hematologic malignancies. Nearly all children with leukemia should have an adequate cytogenetic analysis which in 80-90% is expected to show clonal chromosomal abnormalities. Moreover, with the availability of appropriate gene probes and sophisticated molecular techniques, genetic rearrangements become detectable in the majority of leukemia patients. Genetic abnormalities often associate with particular clinical-biological characteristics of the disease. In ALL, for example, genetic alterations together with distinct immunologic and clinical features, define various subgroups. In AML, unique cytogenetic rea…

Cancer Researchmedicine.medical_specialtyDiseaseBioinformaticsMolecular cytogeneticsAcute lymphocytic leukemiamedicineHumansClinical significanceChildChromosome AberrationsGene RearrangementLeukemiaPloidiesbusiness.industryMyelodysplastic syndromesCytogeneticsHematologyGene rearrangementPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLeukemia Myeloid AcuteLeukemiaOncologyMyelodysplastic SyndromesImmunologybusinessLeukemia
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

Italian registry of patients off therapy after childhood acute lymphoblastic leukemia. Results after first phase of data collection

1986

The Italian Registry of Off-Therapy patients after childhood tumors now includes 760 subjects with acute lymphoblastic leukemia. These patients were all removed from treatment by December 31, 1981, and were followed in 35 different institutions. All the children have received multiple-drug treatment, combined, in 79.7% of the cases, with cranial irradiation. Thirty-nine (5%) experienced a relapse before treatment suspension. Total duration of antileukemic therapy ranges between 18 and 131 months (median, 38). At the last updating (December 31, 1981), 699 subjects were alive, 6 were lost to follow-up, and 55 had died. Life-table analysis shows that 90.8% were alive and 77% were alive in cont…

Cancer Researchmedicine.medical_specialtyPediatricsbusiness.industryLymphoblastic Leukemiamedicine.diseaseOncologyEl NiñoMale patientAcute lymphocytic leukemiaEpidemiologyFemale patientmedicinebusinessChildhood Acute Lymphoblastic LeukemiaAfter treatmentCancer
researchProduct